APREA THERAPEUTICS INC
APRENASDAQ🏆 #4938 by market capEarnings Nov 10US Equity
$0.53▲ $0.09 (+20.12%)
Market closed · at closeTrack APRE
Get earnings, price moves & breaking news on Telegram
24h▲ 20.1%
7d▼ 3.2%
14d▼ 14.0%
30d▼ 31.7%
ytd▼ 38.1%
1y▼ 63.3%
🏦Market Cap
$7M
Small Cap
📈Revenue Growth (YoY)
-100.0%
Declining
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- $0.43 – $0.53
- 52-Week Range
- $0.41 – $1.49
- Volume (shares)
- 1,314
- Avg Volume (shares)
- —
- Shares Outstanding
- 12.6M
- Next Earnings
- 2026-11-10
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- -0.5
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-0.23
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +29.1%
APREA THERAPEUTICS INC
APREFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▼ −100.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
-523.2%▼ −629.6% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$13M▼ −7.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$13M▼ −5.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
7.7M▲ +29.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$15M▼ −$8M YoY
StockOtter · stockotter.spaceAbout APREA THERAPEUTICS INC
Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The company's primary drug candidate, ATRN-119, is an oral ATR inhibitor currently undergoing Phase 1/2a clinical trials for patients with advanced solid tumors. Beyond this lead compound, Aprea's developmental pipeline includes ATRN-Backup, which is also an ATR inhibitor; ATRN-W1051, being explored for its anti-tumor effects; and ATRN-DDRi. Aprea Therapeutics, Inc. is headquartered in Boston, Massachusetts.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst Ratings
ⓘConsensus
Buy
9 analysts
Strong Buy3
Buy5
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026
Latest News & Updates
News unavailable.